Provided by Tiger Trade Technology Pte. Ltd.

AxoGen

31.70
+0.31000.99%
Post-market: 31.42-0.2800-0.88%19:59 EST
Volume:1.06M
Turnover:33.62M
Market Cap:1.46B
PE:-647.28
High:32.77
Open:31.39
Low:31.00
Close:31.39
52wk High:34.24
52wk Low:9.22
Shares:46.12M
Float Shares:45.24M
Volume Ratio:1.27
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0490
EPS(LYR):-0.2251
ROE:-1.90%
ROA:1.21%
PB:12.10
PE(LYR):-140.80

Loading ...

Axogen CFO Lindsey Marie Hartley Reports Disposal of Common Shares

Reuters
·
Yesterday

Axogen Inc. to Present at J.P. Morgan 2026 Healthcare Conference

Reuters
·
Dec 17

Axogen EVP and General Counsel Marc A. Began Reports Sale of Common Shares

Reuters
·
Dec 13

Trade Alert: President Of Axogen Michael Dale Has Sold Stock

Simply Wall St.
·
Dec 12

Axogen Chief Marketing Officer Jens Kemp Reports Sale of Common Shares

Reuters
·
Dec 11

Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE

Simply Wall St.
·
Dec 07

Axogen Inc. Raises CFO Lindsey Hartley’s Salary and Bonus Target

Reuters
·
Dec 06

Axogen Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 06

Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025

Simply Wall St.
·
Dec 06

AxoGen, Inc. : H.c. Wainwright Raises Target Price to $39 From $26

THOMSON REUTERS
·
Dec 05

U.S. RESEARCH ROUNDUP- American Tower, CME Group, Ulta Beauty

Reuters
·
Dec 05

AxoGen Inc : Canaccord Genuity Raises Target Price to $37 From $27

THOMSON REUTERS
·
Dec 05

BUZZ-U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount Skydance

Reuters
·
Dec 05

Axogen Is Maintained at Buy by Lake Street

Dow Jones
·
Dec 05

Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday

MT Newswires Live
·
Dec 04

AxoGen Inc : Jefferies Raises Target Price to $36 From $29

THOMSON REUTERS
·
Dec 04

BUZZ-U.S. STOCKS ON THE MOVE-Salesforce, Dollar General, gold miners

Reuters
·
Dec 04

AxoGen Shares Rise 6.8% Premarket After FDA Approves Co's Nerve Repair Graft

THOMSON REUTERS
·
Dec 04

BRIEF-Axogen Announces FDA Approval Of Biologics License Application For Avance (Acellular Nerve Allograft–Arwx)

Reuters
·
Dec 04

AxoGen Announces FDA Approval of Biologics License Application for Avance® (Acellular Nerve Allograft–Arwx)

THOMSON REUTERS
·
Dec 04